4.7 Review

Mast cell and eosinophil surface receptors as targets for anti-allergic therapy

期刊

PHARMACOLOGY & THERAPEUTICS
卷 170, 期 -, 页码 37-63

出版社

PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.pharmthera.2016.10.010

关键词

Activating receptors; Allergy; Anti-allergic therapy; Eosinophils; Inhibitory receptors; Mast cells

资金

  1. Israel Science Foundation [213/05]
  2. Aimwell Charitable Trust (UK)
  3. Emalie Gutterman Memorial Endowed Fund for COPD related research (USA)
  4. Israel Cancer Association [20161131]
  5. Rosetrees Trust (UK)
  6. United States - Israel Binational Science Foundation (BSF) [2015045]
  7. Hebrew University of Jerusalem, Israel
  8. Rosetrees Trust [M416] Funding Source: researchfish

向作者/读者索取更多资源

Allergy is the host immune response towards harmless substances, called allergens. Allergic diseases comprise allergic asthma, allergic rhinitis, allergic conjunctivitis, atopic dermatitis, and food allergy. While some drugs counteract the symptoms and the inflammation arising from allergy, no completely effective and acceptable side effect free drug has been developed as yet. Moreover, severe asthma and atopic dermatitis are classified as unmet clinical needs. Mast cells and eosinophils are the main effector cells of the allergic response and thus, must be the first cells targeted to impede the allergic inflammation symptoms and evolution. The presence on mast cells and eosinophils of several surface receptors with either activating or inhibitory functions indicates the possibility of their pharmacological targeting. This review deals with some of the receptors expressed on mast cells and eosinophils and their ligand(s). Some receptors have already been exploited as drug targets and others can be feasibly utilized as novel targets for anti-allergic therapy. (C) 2016 Elsevier Inc. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据